Brevan Howard Capital Management LP Has $1.55 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Brevan Howard Capital Management LP boosted its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 48.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 17,751 shares of the biotechnology company's stock after buying an additional 5,794 shares during the period. Brevan Howard Capital Management LP's holdings in Blueprint Medicines were worth $1,548,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Torray Investment Partners LLC lifted its stake in Blueprint Medicines by 1.1% in the fourth quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company's stock valued at $1,439,000 after acquiring an additional 186 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Blueprint Medicines by 0.7% in the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock valued at $3,259,000 after purchasing an additional 265 shares during the period. Summit Investment Advisors Inc. lifted its stake in Blueprint Medicines by 4.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,652 shares of the biotechnology company's stock valued at $580,000 after purchasing an additional 283 shares during the last quarter. Pitcairn Co. grew its holdings in Blueprint Medicines by 2.8% during the fourth quarter. Pitcairn Co. now owns 10,608 shares of the biotechnology company's stock worth $925,000 after purchasing an additional 293 shares during the period. Finally, Hillsdale Investment Management Inc. increased its position in Blueprint Medicines by 0.6% during the fourth quarter. Hillsdale Investment Management Inc. now owns 50,830 shares of the biotechnology company's stock worth $4,433,000 after buying an additional 310 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Needham & Company LLC decreased their target price on Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating on the stock in a report on Monday, April 28th. HC Wainwright reissued a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, May 2nd. Wolfe Research began coverage on shares of Blueprint Medicines in a report on Tuesday, March 18th. They set an "outperform" rating for the company. Morgan Stanley assumed coverage on shares of Blueprint Medicines in a report on Thursday, March 20th. They issued an "equal weight" rating and a $100.00 price target on the stock. Finally, JMP Securities restated a "market outperform" rating and set a $125.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $126.56.

Insider Buying and Selling

In other news, COO Christina Rossi sold 2,274 shares of the firm's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $101.75, for a total transaction of $231,379.50. Following the completion of the transaction, the chief operating officer now owns 66,992 shares of the company's stock, valued at approximately $6,816,436. This trade represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ariel Hurley sold 3,203 shares of Blueprint Medicines stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the transaction, the insider now owns 18,270 shares in the company, valued at approximately $1,692,167.40. This trade represents a 14.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,503 shares of company stock worth $1,027,931 in the last three months. 4.21% of the stock is owned by corporate insiders.

Blueprint Medicines Price Performance

Shares of BPMC stock traded down $1.02 during trading hours on Friday, reaching $97.74. The company's stock had a trading volume of 621,844 shares, compared to its average volume of 779,246. Blueprint Medicines Co. has a fifty-two week low of $73.04 and a fifty-two week high of $121.90. The firm's 50 day simple moving average is $88.49 and its 200-day simple moving average is $93.74. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The company has a market capitalization of $6.31 billion, a price-to-earnings ratio of -90.50 and a beta of 0.83.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.32). The business had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The business's quarterly revenue was up 55.5% compared to the same quarter last year. During the same period last year, the business earned $1.40 earnings per share. Sell-side analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.